You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀-B(01952.HK)治療乳腺癌藥物研究達總體緩解率主要終點
阿思達克 11-11 09:04
雲頂新耀-B(01952.HK)公布,針對戈沙妥珠單抗(在美國以Trodelvy為商品名銷售)治療轉移性三陰性乳腺癌的2b期EVER-132-001研究,達到其總體緩解率的主要終點。 EVER-132-001是一項單臂、多中心的2b期註冊研究,在中國招募80名患者評估戈沙妥珠單抗的用於治療既往接受過至少兩種系統治療(其中至少一種為針對轉移性疾病的治療)的不可切除的局部晚期或轉移性三陰性乳腺癌成人患者的療效。 研究結果顯示經獨立審評委員會評估的總體緩解率為38.8%(置信區間:95%)。戈沙妥珠單抗的安全性特徵與此前研究中所報告的相似,並未發現新的安全性信號。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account